Citadel Advisors
ARGS

Citadel Advisors’s Argos Therapeutics, Inc. ARGS Stock Holding History

Citadel Advisors’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-595
Closed -$4K – 8580
2017
Q2 		$4K Buy
+595
New +$5.07K ﹤0.01% 7398

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citadel Advisors's ARGS Position: Q3 2017 in Review

Citadel Advisors sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2017, closing a stake of 899 shares — an estimated $7K sold.

Citadel Advisors first reported a position in ARGS in Q2 2017 and held it in 1 quarter. The position peaked at $7K in Q2 2017. 29 funds tracked by Wall St. Rank hold ARGS as of Q3 2017.

  • Citadel Advisors reported no remaining Argos Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Citadel Advisors sold 899 Argos Therapeutics, Inc. shares in Q3 2017, an estimated $7K.
  • Citadel Advisors first reported a position in Argos Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Citadel Advisors's Argos Therapeutics, Inc. position peaked at $7K in Q2 2017.
  • 29 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.